Genome scan of clot lysis time and its association with thrombosis in a protein C-deficient kindred
- PMID: 21575129
- PMCID: PMC3138551
- DOI: 10.1111/j.1538-7836.2011.04343.x
Genome scan of clot lysis time and its association with thrombosis in a protein C-deficient kindred
Abstract
Background: Previously, we found increased clot-lysis time (CLT), as measured with a plasma-based assay, to increase the risk of venous thrombosis in two population-based case-control studies. The genes influencing CLT are as yet unknown.
Patients/methods: We tested CLT as risk factor for venous thrombosis in Kindred Vermont II (n = 346), a pedigree suffering from a high thrombosis risk, partially attributable to a type I protein C deficiency. Furthermore, we tested for quantitative trait loci (QTLs) for CLT, using variance component linkage analysis.
Results: Protein C-deficient family members had shorter CLTs than non-deficient members (median CLT 67 min vs. 75 min). One standard deviation increase in CLT increased the risk of venous thrombosis 2.4-fold in non-deficient family members. Protein C deficiency without elevated CLT increased the risk 6.9-fold. Combining both risk factors yielded a 27.8-fold increased risk. The heritability of CLT was 42-52%. We found suggestive evidence of linkage on chromosome 11 (62 cM), partly explained by the prothrombin 20210A mutation, and on chromosome 13 (52 cM). Thrombin-activatable fibrinolysis inhibitor genotypes did not explain the variation in CLT.
Conclusion: Hypofibrinolysis appears to increase thrombosis risk in this family, especially in combination with protein C deficiency. Protein C deficiency is associated with short CLT. CLT is partly genetically regulated. Suggestive QTLs were found on chromosomes 11 and 13.
© 2011 International Society on Thrombosis and Haemostasis.
Similar articles
-
Plasma fibrin clot properties in the G20210A prothrombin mutation carriers following venous thromboembolism: the effect of rivaroxaban.Thromb Haemost. 2017 Aug 30;117(9):1739-1749. doi: 10.1160/TH17-01-0060. Epub 2017 Aug 3. Thromb Haemost. 2017. PMID: 28771277
-
Synergistic effects of hypofibrinolysis and genetic and acquired risk factors on the risk of a first venous thrombosis.PLoS Med. 2008 May 6;5(5):e97. doi: 10.1371/journal.pmed.0050097. PLoS Med. 2008. PMID: 18462012 Free PMC article.
-
Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1.Blood. 2010 Jul 8;116(1):113-21. doi: 10.1182/blood-2010-02-267740. Epub 2010 Apr 12. Blood. 2010. PMID: 20385790
-
Prolonged clot lysis time increases the risk of a first but not recurrent venous thrombosis.Br J Haematol. 2016 Mar;172(6):947-53. doi: 10.1111/bjh.13911. Epub 2016 Jan 15. Br J Haematol. 2016. PMID: 26773756 Review.
-
Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice.Front Biosci. 2002 Feb 1;7:d556-68. doi: 10.2741/A794. Front Biosci. 2002. PMID: 11815293 Review.
References
-
- Guimaraes AH, de Bruijne EL, Lisman T, Dippel DW, Deckers JW, Poldermans D, Rijken DC, Leebeek FWG. Hypofibrinolysis is a risk factor for arterial thrombosis at young age. Br J Haematol. 2009;145:115–120. - PubMed
-
- Lisman T, de Groot PG, Meijers JCM, Rosendaal FR. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood. 2005;105:1102–1105. - PubMed
-
- Meltzer ME, Doggen CJM, de Groot PhG, Rosendaal FR, Lisman T. Reduced plasma fibrinolytic capacity as a potential risk factor for a first myocardial infarction in young men. Br J Haematol. 2009;145:121–127. - PubMed
-
- Meltzer ME, Lisman T, de Groot PG, Meijers JC, le CS, Doggen CJ, Rosendaal FR. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood. 2010;116:113–121. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical